Trials / Completed
CompletedNCT00813046
Safety and Tolerance Study of Grass Pollen-derived Peptides to Treat Allergic Rhinitis
Preliminary Assessment of the Short Term Clinical Tolerability and Safety of Grass Pollen-derived Peptides for Oral Use in Antigen-specific Immunotherapy of Seasonal Allergic Rhinoconjunctivitis
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- BioTech Tools S.A. · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether the oral administration of grass pollen peptides to treat allergic rhinitis is safe and well tolerated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | gpASIT+TM | oral administration of entero-coated capsules containing increasing doses of gpASIT+TM (25 to 1600µg), one dose per day for 4 days |
Timeline
- Start date
- 2008-12-01
- Primary completion
- 2009-01-01
- Completion
- 2009-01-01
- First posted
- 2008-12-22
- Last updated
- 2014-05-26
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT00813046. Inclusion in this directory is not an endorsement.